Skip to main content
Atrás
APLS logo

Apellis Pharmaceuticals, Inc.

Calidad de datos: 100%
APLS
NASDAQ Healthcare Biotechnology
$17.72
▲ $0.49 (2.84%)
Cap. Mercado: 2.27B
Rango del Día
$17.39 $17.96
Rango de 52 Semanas
$16.10 $30.48
Volumen
1,768,591
Promedio 50D / 200D
$21.38 / $22.48
Cierre Anterior
$17.23

Quick Summary

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (631 pares)

Métrica Acción Mediana del Sector
P/E 101.2 0.2
P/B 6.1 3.0
ROE % 7.5 3.6
Net Margin % 2.2 3.8
Rev Growth 5Y % 97.1 9.9
D/E 1.3 0.2

Precio Objetivo de Analistas

Hold
$33.50 +89.1%
Low: $19.00 High: $52.00
EPS Futuro
-$1.12
Ingresos Est.
861.52M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2030 $2.48
$2.15 – $2.80
 1.54B 8
FY2029 $1.50
$1.30 – $1.70
 1.37B 10
FY2028 $1.18
-$0.93 – $7.96
 1.26B 18

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-24 -$0.37 -$0.47 -25.7%
2025-10-30 $1.03 $1.67 +62.1%
2025-07-31 -$0.44 -$0.33 +25.0%
2025-05-07 -$0.36 -$0.74 -105.6%
2025-02-28 -$0.37 -$0.29 +21.6%
2024-11-05 -$0.32 -$0.46 -43.8%
2024-08-01 -$0.33 -$0.28 +15.2%
2024-05-07 -$0.54 -$0.54 0.0%

Dividend History

Yield

0.00%

Payout Ratio

0.00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Puntos Clave

Revenue grew 97.06% annually over 5 years — strong growth
Generating 45.01M in free cash flow
P/E of 101.18 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 68.60%
Cash machine — converts 201.06% of earnings into free cash flow
Capital efficient — spends only 0.03% of revenue on capex

Crecimiento

Revenue Growth (5Y)
97.06%
Revenue (1Y)28.46%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
7.48%
ROIC4.85%
Net Margin2.23%
Op. Margin5.52%

Seguridad

Debt / Equity
1.31
Current Ratio3.14
Interest Coverage1.25

Valoración

P/E Ratio
101.18
Forward P/EN/A
P/B Ratio6.12
EV/EBITDA41.20
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 28.46% Revenue Growth (3Y) 59.09%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 97.06% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.00B Net Income (TTM) 22.39M
ROE 7.48% ROA 2.08%
Gross Margin 89.81% Operating Margin 5.52%
Net Margin 2.23% Free Cash Flow (TTM) 45.01M
ROIC 4.85% FCF Growth (3Y) N/A
Safety
Debt / Equity 1.31 Current Ratio 3.14
Interest Coverage 1.25
Dividends
Dividend Yield 0.00% Payout Ratio 0.00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 101.18 Forward P/E N/A
P/B Ratio 6.12 P/S Ratio 2.26
PEG Ratio -1.27 Forward PEG N/A
EV/EBITDA 41.20 Fwd EV/EBITDA N/A
Forward P/S 2.63 Fwd Earnings Yield N/A
FCF Yield 1.99%
Market Cap 2.27B Enterprise Value 2.28B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.00B 781.37M 396.59M 75.42M 66.56M
Net Income 22.39M -197.88M -528.63M -652.17M -746.35M
EPS (Diluted) 0.18 -1.60 -4.45 -6.15 -8.84
Gross Profit 901.55M 663.64M 338.08M 69.79M 61.36M
Operating Income 55.43M -164.98M -517.12M -594.61M -536.28M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.08B 885.05M 788.73M 760.22M 881.77M
Total Liabilities 705.11M 656.51M 594.21M 590.35M 683.10M
Shareholders' Equity 370.15M 228.54M 194.52M 169.87M 198.66M
Total Debt 486.31M 469.78M 110.93M 112.71M 210.22M
Cash & Equivalents 467.76M 411.29M 351.19M 551.80M 640.19M
Current Assets 1.01B 788.95M 766.33M 719.52M 824.05M
Current Liabilities 323.60M 185.51M 247.59M 167.61M 131.85M